See more : Post Holdings Partnering Corporation (PSPC-WT) Income Statement Analysis – Financial Results
Complete financial analysis of Forte Biosciences, Inc. (FBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Forte Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TAL Education Group (TAL) Income Statement Analysis – Financial Results
- Phoenix Mecano AG (PMN.SW) Income Statement Analysis – Financial Results
- Northern Electric PLC (NTEA.L) Income Statement Analysis – Financial Results
- Wittchen S.A. (WTN.WA) Income Statement Analysis – Financial Results
- All American Pet Company, Inc. (AAPT) Income Statement Analysis – Financial Results
Forte Biosciences, Inc. (FBRX)
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.04M | 41.00K | 49.00K | 51.00K |
| Cost of Revenue | 9.00K | 0.00 | 36.00K | 54.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | -36.00K | -54.00K | -11.00K | 18.04M | 41.00K | 49.00K | 51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.86M | 5.59M | 13.85M | 10.00M | 2.68M | 50.46M | 29.11M | 27.22M | 19.17M |
| General & Administrative | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 265.68K | 8.56M | 4.52M | 3.83M |
| Selling & Marketing | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 12.54M | -292.00K | -255.00K | -232.00K |
| SG&A | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 12.81M | 8.27M | 4.27M | 3.60M |
| Other Expenses | -1.00 | 17.00K | -222.00K | -205.00K | -6.85K | 0.00 | 0.00 | -50.00K | 0.00 |
| Operating Expenses | 32.48M | 13.90M | 21.49M | 14.23M | 4.06M | 63.26M | 37.38M | 31.49M | 22.77M |
| Cost & Expenses | 32.49M | 13.90M | 21.49M | 14.23M | 4.06M | 63.89M | 37.67M | 31.74M | 23.01M |
| Interest Income | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 595.00K | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 173.38K | 1.93M | -1.84M | -102.00K | |
| Depreciation & Amortization | 9.00K | 36.00K | 36.00K | 54.00K | 11.00K | 625.00K | 292.00K | 255.00K | 232.00K |
| EBITDA | -32.48M | -13.90M | -21.45M | -46.43M | -4.05M | -43.69M | -36.71M | -31.17M | -22.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -250.77% | -91,065.85% | -64,155.10% | -44,552.94% |
| Operating Income | -32.49M | -13.90M | -21.49M | 17.83M | -4.06M | -45.85M | -37.63M | -31.69M | -22.95M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254.23% | -91,778.05% | -64,675.51% | -45,007.84% |
| Total Other Income/Expenses | 1.01M | 17.00K | -222.00K | -205.00K | -5.00K | -1.40M | -1.30M | -1.79M | -102.00K |
| Income Before Tax | -31.48M | -13.88M | -21.71M | -46.49M | -4.07M | -47.26M | -38.93M | -33.48M | -23.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -262.01% | -94,948.78% | -68,322.45% | -45,207.84% |
| Income Tax Expense | 0.00 | -17.00K | -200.56K | 32.06M | -2.52K | 1.70M | -2.60M | -3.67M | -204.00K |
| Net Income | -31.48M | -13.86M | -21.71M | -78.54M | -4.07M | -48.96M | -38.93M | -33.48M | -23.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -271.43% | -94,948.78% | -68,322.45% | -45,207.84% |
| EPS | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| EPS Diluted | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| Weighted Avg Shares Out | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
| Weighted Avg Shares Out (Dil) | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021. Conference Call and Webcast Information Forte management will host a conference call...
Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021. Conference Call and Webcast Information Forte management will host a conference call...
Forte Biosciences: Microbiome Therapeutics For Skin Disease
Forte Biosciences is developing a first-in-class drug for eczema, which affects over 16M patients in the US.
Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market
The company's key product candidate is FB-401, a topical live biotherapeutic, with three therapeutic strains of commensal gram-negative bacteria Roseomonas mucosa. FB-401 is being developed in mild to moderate atopic dermatitis and has FDA Fast track designation based on Phase...
Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge
Two new breakout stocks for Week 13 of 2021 with better than 10% short-term upside potential. This past week one selection gained over 10% with KIRK +16.2% in the early part of the week before giving back all its gains...
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021. “Forte made significant progress in the fourth quarter of 2020....
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021. “Forte made significant progress in the fourth quarter of 2020....
Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March 24, 2021. Conference Call and Webcast Information Forte management will host...
Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March 24, 2021. Conference Call and Webcast Information Forte management will host...
Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March 24, 2021. Conference Call and Webcast Information Forte management will host...
Source: https://incomestatements.info
Category: Stock Reports